Less extensive surgery after immunotherapy for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether people with advanced head and neck cancer who respond well to immunotherapy before surgery can have a smaller, less invasive operation. The goal is to preserve more of your normal functions, like speaking and swallowing, while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of head and neck cancer called squamous cell carcinoma (not nasopharyngeal cancer).
- Your cancer is at an advanced stage (III or IV) but has not spread far.
- You are in good overall health (able to care for yourself and up and about).
- You have already received immunotherapy (with or without chemotherapy or targeted therapy) for up to 6 cycles before surgery.
- Your tumor shrank or disappeared after immunotherapy, as seen on scans.
- You have not had surgery or radiation for this cancer before.
- You are willing to have surgery and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether giving an immunotherapy drug called sintilimab before and after surgery can help treat head and neck cancer. The drug aims to boost your immune system to fight the cancer, and the goal is to improve outcomes when combined with the standard surgical treatment.
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Hear when a new Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.